Intellia Therapeutics, Inc.

NTLA

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 1652130

Revenue (Latest FY)

$36.3M

Net Income (Latest FY)

-$481.2M

Industry

In Vitro & In Vivo Diagnostic Substances

Recent Filings

Company Details

CIK1652130

Fiscal Year End1231

CategoryLarge accelerated filer

StateDE

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)